✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Sym004 is an investigational drug.
There have been 11 clinical trials for Sym004. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2019.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Symphogen A/S, Merck KGaA, and Merck KGaA, Darmstadt, Germany.
There are two US patents protecting this investigational drug and thirty-seven international patents.
Recent Clinical Trials for Sym004
|Sym004 Versus TAS-102 in Patients With mCRC||Symphogen A/S||Phase 3|
|Sym004 Versus Futuximab or Modotuximab in Patients With mCRC||Symphogen A/S||Phase 2|
|Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients||Symphogen A/S||Phase 2|
Top disease conditions for Sym004
Top clinical trial sponsors for Sym004
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Sym004||See Plans and Pricing||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||See Plans and Pricing|
|Sym004||See Plans and Pricing||Methods for assessing and identifying or evolving conditionally active therapeutic proteins||Halozyme, Inc. (San Diego, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Sym004||Australia||AU2012340766||2031-11-23||See Plans and Pricing|
|Sym004||Brazil||BR112014012539||2031-11-23||See Plans and Pricing|
|Sym004||Canada||CA2856297||2031-11-23||See Plans and Pricing|
|Sym004||China||CN104093743||2031-11-23||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|